Document Type : Original Research

Authors

1 Dept. of Gynecology, School of Medicine, Mashad University of Medical Sciences, Mashhad, Iran

2 Dept. of Pathology, School of Medicine, Mashad University of Medical Sciences, Mashhad, Iran

3 Dept. of Microbiology, School of Medicine, Mashad University of Medical Sciences, Mashhad, Iran

Abstract

Background and Aims: Ovarian cancer is one of most common causes of cancer related women's mortalities. Human papilloma virus is a known factor concerning cervical cancer but its role in causing ovarian cancer is not yet verified. A few studies also identified HPV DNA in ovarian carcinoma tissues. However, some studies did not detect HPV DNA in ovarian carcinoma tissues. In this article, we investigated the potential role of high risk HPVs in the ovarian epithelial carcinoma.
Methods: Fifty archived epithelial ovarian cancer paraffin blocks were collected. Then, 30 non-malignant ovarian blocks used as control. These samples were histopathologically were confirmed by a pathologist and the proper blocks for DNA extraction and PCR were sorted. PCR was conducted deploying highly specific primers for high-risk types of HPV (18 and 16) according to the instructions of manufacturer company.
Results: High-risk oncogenic sequences were identified in 4 (5%) of the 80 studied samples. Of the 4 HPV positive cases, there was 1 case with normal tissue, 1 case of mucinous cyst adenocarcinoma, and 2 cases of serous cyst adenocarcinoma
Conclusion: Surprisingly, our findings could not support any association between high-risk oncogenic human papilloma virus (18 and 16) and malignant ovarian epithelial cancer. Therefore, that HPV is highly unlikely to play any causal role in the pathogenesis of epithelial ovarian neoplasia.
 

Keywords

  1. Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer. J Reprod Med 2001;46(7):621-9.
  2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351(24):2519-29.
  3. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979;2(8135):170-3.
  4. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11(2):111-7.
  5. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274(24):1926-30.
  6. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002;95(11):2380-9.
  7. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989;49(13):3670-4.
  8. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006;103(3):1122-9.
  9. McMurray HR, Nguyen D, Westbrook TF, McAnce DJ. Biology of human papillomaviruses. Int J Exp Pathol 2001;82(1):15-33.
  10. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001;164(7):1017-25.
  11. Wright TC, Jr., Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103(2):304-9.
  12. Magal SS, Jackman A, Pei XF, Schlegel R, Sherman L. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int J Cancer 1998;75(1):96-104.
  13. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196(10):1438-46.
  14. Munoz N, Manalastas R, Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373(9679):1949-57.
  15. Wu QJ, Guo M, Lu ZM, Li T, Qiao HZ, Ke Y. Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer 2003;89(4):672-5.
  16. Ip SM, Wong LC, Xu CM, Cheung AN, Tsang PC, Ngan HY. Detection of human papillomavirus DNA in malignant lesions from Chinese women with carcinomas of the upper genital tract. Gynecol Oncol 2002;87(1):104-11.
  17. Konidaris S, Kouskouni EE, Panoskaltsis T, Kreatsas G, Patsouris ES, Sarivalassis A, et al. Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women. Health Care Women Int 2007;28(2):182-91.
  18. Beckmann AM, Sherman KJ, Saran L, Weiss NS. Genital-type human papillomavirus infection is not associated with surface epithelial ovarian carcinoma. Gynecol Oncol 1991;43(3):247-51.
  19. Chen TR, Chan PJ, Seraj IM, King A. Absence of human papillomavirus E6-E7 transforming genes from HPV 16 and 18 in malignant ovarian carcinoma. Gynecol Oncol 1999;72(2):180-2.
  20. Anttila M, Syrjanen S, Ji H, Saarikoski S, Syrjanen K. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol 1999;72(3):337-41.
  21. Quirk JT, Kupinski JM, DiCioccio RA. Analysis of ovarian tumors for the presence of human papillomavirus DNA. J Obstet Gynaecol Res 2006;32(2):202-5.
  22. Giordano G, D'Adda T, Gnetti L, Froio E, Merisio C, Melpignano M. Role of human papillomavirus in the development of epithelial ovarian neoplasms in Italian women. J Obstet Gynaecol Res 2008;34(2):210-7.